Product Introduction :
Lorlatinib is a third-generation ALK inhibitor. As a follow-up treatment for crizotinib resistance, it can effectively inhibit the nine mutations that cause crizotinib resistance. It is particularly suitable for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who are resistant to other ALKs.
In 2018, the U.S. FDA officially approved lorlatinib for the treatment of patients with ALK-positive non-small cell lung cancer, including: patients whose disease continues to worsen after receiving crizotinib or at least one other ALK inhibitor, or patients whose disease progresses after receiving alectinib or ceritinib as the first ALK inhibitor therapy.
For patients with ALK-positive non-small cell lung cancer who are receiving the first treatment, the efficacy of larotrectinib is as high as 90%, and the intracranial efficacy is as high as 75%. For patients with ALK-positive disease who have previously received crizotinib, the efficacy of larotrectinib is 69%, and the intracranial efficacy is 68%.
Indications :
Indicated for the treatment of patients with ALK gene-positive non-small cell lung cancer (NSCLC)
Usage and Dosage :
The recommended dose is 100 mg orally once daily
